Arkolith/Insider Trading/DNTH/Form 4

Savitz Ryan

EVP, CFO & CBODianthus Therapeutics, Inc. /DE/ (DNTH) · full profile →Form 4 · filed Apr 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$9.5M
Net Open-Market Flow
-$9.5M
Transactions
12
10 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 31, 2026Option exercise(M)74K$8.44$628K74K
Mar 31, 2026Option exercise(M)40K$17.88$715K114K
Mar 31, 2026Sell(S)1K$78.33$109K113K
Mar 31, 2026Sell(S)22K$78.86$1.7M91K
Mar 31, 2026Sell(S)1K$80.25$119K90K
Mar 31, 2026Sell(S)800$81.36$65K89K
Mar 31, 2026Sell(S)2K$82.84$196K87K
Mar 31, 2026Sell(S)60K$83.90$5.0M27K
Mar 31, 2026Sell(S)19K$84.57$1.6M7K
Mar 31, 2026Sell(S)7K$85.54$619K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2026Option exercise(M)74K—$010K
Mar 31, 2026Option exercise(M)40K—$080K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001992324-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML